SG11201903306SA - Multimeric il-15-based molecules - Google Patents

Multimeric il-15-based molecules

Info

Publication number
SG11201903306SA
SG11201903306SA SG11201903306SA SG11201903306SA SG11201903306SA SG 11201903306S A SG11201903306S A SG 11201903306SA SG 11201903306S A SG11201903306S A SG 11201903306SA SG 11201903306S A SG11201903306S A SG 11201903306SA SG 11201903306S A SG11201903306S A SG 11201903306SA
Authority
SG
Singapore
Prior art keywords
international
co7k
miramar
north
cell
Prior art date
Application number
SG11201903306SA
Inventor
Hing Wong
Warren Marcus
Bai Liu
Wenxin Xu
Robby Newman
Karen Kage
Lijing You
Peter Rhode
Patrick Soon-Shiong
Original Assignee
Altor Bioscience Corp
Nantcell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altor Bioscience Corp, Nantcell Inc filed Critical Altor Bioscience Corp
Publication of SG11201903306SA publication Critical patent/SG11201903306SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1#11101111 0 11101 HOE 3E1 0 011101 Ell 1101111111011101111011011# Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\"1 WO 2018/075989 Al 26 April 2018 (26.04.2018) WI P0 I PC T (51) International Patent Classification: 29th St, Miramar, FL 33025 (US). LIU, Bai; 9631 NW CO7K 14/54 (2006.01) CO7K 14/47 (2006.01) 39th Street, Cooper City, FL 33024 (US). XU, Wenxin; CO7K 14/705 (2006.01) CO7K 16/24 (2006.01) 11917 SW 12th Street, Pembroke Pines, FL 33025 (US). C07K 16/18 (2006.01) C07K 16/28 (2006.01) NEWMAN, Robby; 2810 North Commerce Parkway, Mi- C07K 14/715 (2006.01) C07K 16/30 (2006.01) ramar, FL 33025 (US). KAGE, Karen; 2810 North Com- C07K 14/435 (2006.01) C07K 16/32 (2006.01) merce Parkway, Miramar, FL 33025 (US). YOU, Lijing; (21) International Application Number: 2810 North Commerce Parkway, Miramar, FL 33025 (US). PCT/US2017/057757 RHODE, Peter; 14857 SW 42nd Lane, Miami, FL 33185 (US). SOON-SHIONG, Patrick; 9920 Jefferson Blvd, (22) International Filing Date: Culver City, CA 90232 (US). 21 October 2017 (21.10.2017) (74) Agent: CORLESS, Peter, F. et al.; Mintz Levin Cohn Fer- (25) Filing Language: English ris Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 62/411,216 21 October 2016 (21.10.2016) US AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/513,964 01 June 2017 (01.06.2017) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (71) Applicants: ALTOR BIOSCIENCE CORPORATION DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, [US/US]; 2810 North Commerce Parkway, Miramar, FL HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, _ 33025 (US). NANTCELL, INC. [ /US]; 9920 Jefferson KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, — Boulevard, Culver City, CA 90232 (US). MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = — OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (72) Inventors: WONG, Hing, C.; 2966 Wentworth Street, = Weston, FL 33332 (US). MARCUS, Warren; 8382 SW = = (54) Title: MULTIMERIC IL-15-BASED MOLECULES = FIG. 1 PD-1 s.,,—mi 4, _ = — = Antigen -Specific _ = = . = = \ _ Binding Domains Against .-q 1 , ..), 411111111: PD -L1 s . 1* - 11071; • .. . i P Diseased Cell ,,., 1 S Antigen , , 1, / v 1 ki c \: I e IL-1 5N72D #0L Disease trlir-$ • \ , 1 I i. N..i k I ir 11,'\" APII\" s II r • I i -= ., ,,),;.'' $ — --ke ,,, e il kl4 v Activated T Cell - 4.. = ___ _ A = - -m IL-15Ra _.- PD-1 — m m = — Il M MIgG1 Fc NIQ T Cell / ‘ 1- Macrophage NK Cell / Macrophage 01 r 00 IL-15R07c C:7\ Receptors Low Affinity Fc/ Receptors 11 in IN CZ ---.... Il C:::: ) (57) : The invention features multi- specific protein complexes with one domain comprising IL-15 or a functional variant and ei a binding domain specific to a disease antigen, immune checkpoint or signaling molecule. [Continued on next page] WO 2018/075989 Al MIDEDIMOMOIDEIREIDIONOMIHRIONEVOIMIE SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
SG11201903306SA 2016-10-21 2017-10-21 Multimeric il-15-based molecules SG11201903306SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662411216P 2016-10-21 2016-10-21
US201762513964P 2017-06-01 2017-06-01
PCT/US2017/057757 WO2018075989A1 (en) 2016-10-21 2017-10-21 Multimeric il-15-based molecules

Publications (1)

Publication Number Publication Date
SG11201903306SA true SG11201903306SA (en) 2019-05-30

Family

ID=62019612

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903306SA SG11201903306SA (en) 2016-10-21 2017-10-21 Multimeric il-15-based molecules

Country Status (12)

Country Link
US (3) US20180200366A1 (en)
EP (1) EP3529263A4 (en)
JP (1) JP7492336B2 (en)
KR (2) KR20190091264A (en)
CN (1) CN110799528A (en)
AU (1) AU2017345791B2 (en)
BR (1) BR112019007920A2 (en)
CA (2) CA3200275A1 (en)
IL (1) IL266100B2 (en)
MX (1) MX2019004681A (en)
SG (1) SG11201903306SA (en)
WO (1) WO2018075989A1 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2160401B1 (en) 2007-05-11 2014-09-24 Altor BioScience Corporation Fusion molecules and il-15 variants
EP3673915A1 (en) 2014-06-30 2020-07-01 Altor BioScience Corporation Il-15-based molecules and methods of use thereof
CA3024509A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
WO2017218533A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
PE20191034A1 (en) 2016-10-14 2019-08-05 Xencor Inc BISPECIFIC HETERODIMERIC FUSION PROTEINS CONTAINING FC IL-15 / IL-15R FUSION PROTEINS AND PD-1 ANTIBODY FRAGMENTS
SG11201903306SA (en) 2016-10-21 2019-05-30 Altor Bioscience Corp Multimeric il-15-based molecules
EP3601364A4 (en) * 2017-03-20 2021-01-06 Cancer Therapeutics Laboratories, Inc. Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy
CN111132733A (en) 2017-06-30 2020-05-08 Xencor股份有限公司 Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15R α and an antigen binding domain
WO2019046313A1 (en) 2017-08-28 2019-03-07 Altor Bioscience Llc Il-15-based fusions to il-7 and il-21
EP3678701A4 (en) 2017-09-05 2021-12-01 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
JP2021520829A (en) 2018-04-18 2021-08-26 ゼンコア インコーポレイテッド TIM-3 targeted heterodimer fusion protein containing IL-15 / IL-15RA Fc fusion protein and TIM-3 antigen binding domain
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
CN112334572A (en) * 2018-06-19 2021-02-05 南特细胞公司 HIV treatment compositions and methods
WO2020023713A1 (en) * 2018-07-26 2020-01-30 Nantbio, Inc. Tri-cytokine txm compositions and methods
CN112996805A (en) 2018-08-30 2021-06-18 Hcw生物科技公司 Multi-chain chimeric polypeptides and uses thereof
CN113365663A (en) 2018-08-30 2021-09-07 Hcw生物科技公司 Single-chain chimeric polypeptides and uses thereof
US11730762B2 (en) * 2018-08-30 2023-08-22 HCW Biologics, Inc. Methods for stimulating proliferation or differentiation of an immune cell with a multi-chain chimeric polypeptide
CN112996904A (en) * 2018-09-07 2021-06-18 南特生物公司 Targeted IL-12 therapy and methods for stimulating HANK and NK92MI cells
EP3864047A2 (en) 2018-10-12 2021-08-18 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
CN112567024A (en) * 2018-10-31 2021-03-26 南克维斯特公司 NK cell elimination of PD-L1 positive malignancy by expressing PD-L1 chimeric antigen receptor
US11618776B2 (en) 2018-12-20 2023-04-04 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
EP3976794A2 (en) * 2019-05-31 2022-04-06 City of Hope Cd33 targeted chimeric antigen receptor modified t cells for treatment of cd33 positive malignancies
CN114269903A (en) 2019-06-21 2022-04-01 Hcw生物科技公司 Multi-chain chimeric polypeptides and uses thereof
EP4019536A4 (en) * 2019-08-19 2023-09-06 Nantong Yichen Biopharma. Co. Ltd. Immunocytokine, preparation for same, and uses thereof
CN114787196A (en) * 2019-08-29 2022-07-22 南特生物科学公司 Modified N-810 and methods thereof
RU2753282C2 (en) * 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" IMMUNOCYTOKIN INCLUDING A HETERODIMERIC PROTEIN COMPLEX BASED ON ОСНОВЕ IL-15/IL-15Rα AND ITS APPLICATION
KR20220069026A (en) * 2019-09-26 2022-05-26 리전츠 오브 더 유니버시티 오브 미네소타 NK Participant Compounds Binding to Viral Antigens and Methods of Use
TW202128757A (en) 2019-10-11 2021-08-01 美商建南德克公司 Pd-1 targeted il-15/il-15ralpha fc fusion proteins with improved properties
WO2021099576A1 (en) * 2019-11-21 2021-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel immunotherapies targeting pd-1 with anti-pd-1/il-15 immunocytokines
US20210188933A1 (en) * 2019-12-18 2021-06-24 Nantcell, Inc Methods of treating pancytopenia
IL295278A (en) * 2020-02-05 2022-10-01 Novartis Ag Cho cell expressing il-15 heterodimers
US20220025402A1 (en) 2020-07-22 2022-01-27 Nantcell, Inc. Electroporation With Active Compensation
WO2022042576A1 (en) * 2020-08-27 2022-03-03 盛禾(中国)生物制药有限公司 Multifunctional fusion protein and use thereof
CA3195627A1 (en) * 2020-10-26 2022-05-05 Stefano FERRARA Il-2/il-15r.beta..gamma. agonist for treating squamous cell carcinoma
JP2023550880A (en) * 2020-10-26 2023-12-06 サイチューン ファーマ IL-2/IL-15Rβγ agonist for treating non-melanoma skin cancer
WO2022140701A1 (en) * 2020-12-24 2022-06-30 Xencor, Inc. Icos targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and icos antigen binding domains
CN112795543B (en) * 2021-02-04 2022-09-27 华中农业大学 Hybridoma cell strain, monoclonal antibody secreted by hybridoma cell strain and resisting grass carp IL-15R alpha and application of monoclonal antibody
AU2022217812A1 (en) * 2021-02-05 2023-08-03 Salubris Biotherapeutics, Inc. Il-15 fusion proteins and methods of making and using same
CN114920841B (en) * 2021-02-11 2023-06-09 兰州大学第二医院 anti-CD 87 antibodies and specific chimeric antigen receptors thereof
CN113106068A (en) * 2021-03-26 2021-07-13 深圳市先康达生命科学有限公司 Immune cell of autocrine IL-15 and anti-PD1 fusion protein
EP4351320A1 (en) 2021-06-09 2024-04-17 ImmunityBio, Inc. Methods and systems for producing a protein of interest in a plant
WO2023049832A1 (en) * 2021-09-23 2023-03-30 Sagittarius Bio, Inc. Il-12 and il-15 polypeptides
WO2023086772A1 (en) 2021-11-12 2023-05-19 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
CN115806629A (en) * 2022-08-03 2023-03-17 深圳市先康达生命科学有限公司 Autocrine IL-15 and anti-CTLA4 combined fusion protein and application thereof
CN115806628A (en) * 2022-08-03 2023-03-17 深圳市先康达生命科学有限公司 Autocrine IL-15 and anti-TIGIT combined fusion protein and application thereof
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b
CN116789837B (en) * 2023-03-24 2024-02-23 山西纳安生物科技股份有限公司 Anti-tissue factor humanized antibody, antibody coupling medicine prepared from anti-tissue factor humanized antibody and application of antibody coupling medicine

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5291285A (en) 1976-01-23 1977-08-01 Hitachi Ltd Escalator
JPS5841623B2 (en) 1978-12-25 1983-09-13 株式会社東芝 Mass spectrometer ion detector
JPS5718916A (en) 1980-07-11 1982-01-30 Iseki Agricult Mach Shaking table sorter of automatic feeding type thresher
JPS5770185A (en) 1980-10-21 1982-04-30 Kazuo Makino Preparation of blended oil for coal liquefaction
JPS57144287A (en) 1981-03-02 1982-09-06 Toray Ind Inc Cyclopentabenzofuran derivative
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1994004689A1 (en) 1992-08-14 1994-03-03 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Recombinant toxin with increased half-life
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
JPH09512165A (en) 1994-04-06 1997-12-09 イミュネックス・コーポレーション Interleukin 15
DK0772624T3 (en) 1994-04-06 2000-11-13 Immunex Corp Interleukin-15
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US7008624B1 (en) 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5534592A (en) 1995-09-22 1996-07-09 The Goodyear Tire & Rubber Company High performance blend for tire treads
ATE279947T1 (en) 1996-03-18 2004-11-15 Univ Texas IMMUNOGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-LIFE TIMES
DE69733610T2 (en) 1996-04-26 2006-05-11 Beth Israel Deaconess Medical Center, Inc., Boston INTERLEUKIN-15 ANTAGONISTS
ZA981478B (en) 1997-02-21 1998-08-24 Vlaams Interuniv Inst Biotech Use of interleukin-15
CA2408691A1 (en) 2000-05-12 2001-11-22 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
EP1289564B1 (en) 2000-06-05 2018-07-18 Altor BioScience Corporation T cell receptor fusions and conjugates and methods of use thereof
DE60138222D1 (en) 2000-09-14 2009-05-14 Beth Israel Hospital MODULATION OF IL-2 AND IL-15 MEDIATED T ZONE LANGUAGES
US20030180888A1 (en) 2000-11-03 2003-09-25 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules, and uses thereof
KR100708398B1 (en) 2002-03-22 2007-04-18 (주) 에이프로젠 Humanized antibody and process for preparing same
WO2004028339A2 (en) 2002-09-27 2004-04-08 Brigham And Women's Hospital, Inc. Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
EA015897B1 (en) 2003-02-26 2011-12-30 Генмаб А/С Use of human monoclonal antibody to il-15 comprising a composition and medical preparation (variants), composition and medical preparation containing them
DE10324708A1 (en) 2003-05-30 2004-12-16 Ltn Servotechnik Gmbh Slip ring element and method for its production
CN1233822C (en) 2003-09-05 2005-12-28 中国科学技术大学 Interleukin-15 gene modified natural killing cell strain and its preparation method
WO2005046449A2 (en) 2003-11-10 2005-05-26 Altor Bioscience Corporation Soluble tcr molecules and methods of use
WO2005085282A1 (en) 2004-02-27 2005-09-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity
EP1586585A1 (en) 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Expression system for the production of IL-15/Fc fusion proteins and their use
CN100334112C (en) 2004-10-15 2007-08-29 上海海欣生物技术有限公司 Interfusion protein of human interleukin 15 and Fe
EP1814580B1 (en) 2004-11-24 2016-08-10 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
JP2008523132A (en) 2004-12-13 2008-07-03 サイトス バイオテクノロジー アーゲー IL-15 antigen array and method of use thereof
PL3263581T3 (en) 2005-05-17 2021-05-04 University Of Connecticut Compositions and methods for immunomodulation in an organism
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
PL1873166T3 (en) 2006-06-30 2011-03-31 Conaris Res Institute Ag Improved sgp 130Fc dimers
US7965180B2 (en) 2006-09-28 2011-06-21 Semiconductor Energy Laboratory Co., Ltd. Wireless sensor device
CA2967847C (en) 2007-03-30 2023-08-01 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
EP2160401B1 (en) 2007-05-11 2014-09-24 Altor BioScience Corporation Fusion molecules and il-15 variants
AU2013273643C1 (en) 2007-05-11 2016-08-11 Altor Bioscience Corporation Fusion molecules and il-15 variants
US8252897B2 (en) 2007-06-21 2012-08-28 Angelica Therapeutics, Inc. Modified toxins
WO2009002562A2 (en) 2007-06-27 2008-12-31 Marine Polymer Technologies, Inc. Complexes of il-15 and il-15ralpha and uses thereof
US7837588B2 (en) 2007-07-20 2010-11-23 American Axle & Manufacturing, Inc. Pre-load mechanism for helical gear differential
WO2009117117A1 (en) 2008-03-19 2009-09-24 Altor Bioscience Corporation T cell receptor fusions and conjugates and methods of use there of
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
DK3327040T3 (en) 2010-09-21 2021-09-20 Altor Bioscience Corp MULTIMERIC SOLUBLE IL-15 FUSION MOLECULES AND METHODS OF PREPARING AND USING THE SAME
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
WO2013163427A1 (en) * 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
MX2014014682A (en) 2012-06-18 2015-03-04 Novartis Ag Stabilized gp120.
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014028776A1 (en) 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
SI2908912T1 (en) 2012-10-18 2021-03-31 The Rockefeller University Broadly-neutralizing anti-hiv antibodies
CA2888896A1 (en) 2012-10-24 2014-05-01 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
JP2017509319A (en) * 2014-01-15 2017-04-06 カドモン コーポレイション，リミティド ライアビリティ カンパニー Immunomodulator
EP3673915A1 (en) 2014-06-30 2020-07-01 Altor BioScience Corporation Il-15-based molecules and methods of use thereof
CN104672325A (en) 2015-03-11 2015-06-03 福建农林大学 Method for preparing phycocyanin from fresh spirulina
US10562960B2 (en) * 2015-03-20 2020-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to gp120 and their use
CA2999294A1 (en) 2015-09-25 2017-03-30 Altor Bioscience Corporation Interleukin-15 superagonist significantly enhances graft-versus-tumor activity
KR102463844B1 (en) 2016-05-27 2022-11-08 알토 바이오사이언스 코포레이션 Construction and Characterization of Multimeric IL-15-Based Molecules with CD3 Binding Domains
SG11201903306SA (en) 2016-10-21 2019-05-30 Altor Bioscience Corp Multimeric il-15-based molecules
CA3089333C (en) 2018-03-26 2023-10-10 Altor Bioscience Llc Anti-pdl1, il-15 and tgf-beta receptor combination molecules

Also Published As

Publication number Publication date
AU2017345791B2 (en) 2020-10-22
IL266100B2 (en) 2023-02-01
WO2018075989A1 (en) 2018-04-26
MX2019004681A (en) 2019-10-07
CA3041310C (en) 2023-09-05
JP7492336B2 (en) 2024-05-29
CA3200275A1 (en) 2018-04-26
US20200261575A1 (en) 2020-08-20
JP2019533449A (en) 2019-11-21
KR102392142B1 (en) 2022-04-28
AU2017345791A1 (en) 2019-05-09
US11318201B2 (en) 2022-05-03
BR112019007920A2 (en) 2019-10-08
IL266100A (en) 2019-06-30
CN110799528A (en) 2020-02-14
US20210196821A1 (en) 2021-07-01
KR20210062749A (en) 2021-05-31
EP3529263A4 (en) 2020-07-08
CA3041310A1 (en) 2018-04-26
US11369679B2 (en) 2022-06-28
EP3529263A1 (en) 2019-08-28
US20180200366A1 (en) 2018-07-19
KR20190091264A (en) 2019-08-05
IL266100B (en) 2022-10-01

Similar Documents

Publication Publication Date Title
SG11201903306SA (en) Multimeric il-15-based molecules
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201901066UA (en) Novel alkaline stable immunoglobulin-binding proteins
SG11201900201YA (en) Methods for quantitating individual antibodies from a mixture
SG11201901950TA (en) Methods of treating immune disorders using pd-1 binding proteins
SG11201905699XA (en) Anti-icos agonist antibodies and uses thereof
SG11201811184UA (en) Lag -3 binding members
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201909999RA (en) Linked multiple blockchain system
SG11201906264YA (en) Improved serum albumin binders
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201906341XA (en) Improved serum albumin binders
SG11201907580SA (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11201806992VA (en) Antibodies to tigit
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201906961UA (en) Polypeptide variants and uses thereof
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201408224SA (en) Novel ruthenium complexes, their use in the metathesis reactions, and a process for carrying out the metathesis reaction
SG11201906319XA (en) Compositions and methods for the depletion of cd137+ cells
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201907671XA (en) Systems and methods for cracking hydrocarbon streams such as crude oils utilizing catalysts which include zeolite mixtures
SG11201907253VA (en) Proteins binding bcma, nkg2d and cd16